Abstract 1845P
Background
ICIs are used in many solid tumors and is better tolerated than chemotherapy. However, irAEs are a concerning toxicity. Studies suggest that BMI may influence irAEs rates. We conducted a population-level study to evaluate BMI on irAEs and acute care use in patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of solid tumors patients initiating ICI therapy in Ontario, Canada from June 2012-October 2018. We collected information on socio-demographics including BMI at start of ICI, clinical covariates and outcomes including acute care use and irAEs within 120 days of the last ICI dose. Multivariable Fine Gray competing risk analyses evaluated the impact of BMI on irAEs and acute care use, treating death as a competing event.
Results
Among 4683 patients, median age was 67, 57% were male; 46% had lung cancer, 35% melanoma, 9% renal; Median BMI was 26.1 (3% low, 29% normal, 27% overweight, 19% obese). Overall, 57% had an acute care episode while 7% of patients had an irAE requiring hospitalization. Increased BMI was associated with increased rate of irAEs (aHR=1.03 per 1 unit increase, 95% CI [1.01-1.04] p<0.001). Compared to patients with normal BMI, obese (aHR=1.60 [1.21-2.11] p<0.001) patients had a higher rate of irAEs. Subgroup analysis by gender found that females with increasing BMI (aHR=1.03 per unit increase [1.00-1.06] p=0.02) and obesity (aHR=2.01 [1.30-3.09] p=0.002) had higher rates of irAEs. Disease site analyses found that in patients with melanoma, obesity when compared to normal BMI (aHR=1.67 [1.10-2.53] p=0.02) was associated with increase in irAEs. In particular, in females with melanoma, obesity compared to normal BMI was strongly associated with increased irAEs (aHR=2.60 [1.36-4.96] p<0.004). BMI was not associated with overall general acute care use as a continuous or categorical variable (p>0.05).
Conclusions
Increasing BMI and obesity is associated with increasing risk for irAEs but not acute care use. The association was strongest for female patients and those with melanoma. Further research is needed to understand the mechanism of action behind this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Eng.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1895P - Higher modified Glasgow Prognostic Score in cancer patients at the Emergency Department is associated with an increased risk of hospital admissions
Presenter: Dominikus Huber
Session: Poster session 12
1896P - Importance of prompt medical oncologist (MO) consultation at the Emergency Department (ED): A prospective study in a tertiary hospital on 10,896 admissions in the first quarter of 2024
Presenter: Cristina Morelli
Session: Poster session 12
1897P - Time to access to diagnosis and treatment for lung cancer (LC): Experience within an Italian comprehensive cancer center
Presenter: Simone Nardin
Session: Poster session 12
1898P - Efficacy of virtual reality-based interventions in cancer-related symptom management in AYA's: A systematic review
Presenter: Nikolina Dodlek
Session: Poster session 12
1899P - Cannabinoids for cancer-associated symptoms: A systematic review and meta-analysis
Presenter: Ioana Creanga-Murariu
Session: Poster session 12
1900P - Seasonal impact on subcutaneous port infections among oncological patients
Presenter: David Kiesl
Session: Poster session 12
1901P - State of supportive care in oncology 2024: Tumor types, industry support, endpoints, and trial locations
Presenter: David Benjamin
Session: Poster session 12
1902P - Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective
Presenter: Tarek Hijal
Session: Poster session 12
1904P - Factors and trends associated with alcohol intake in patients with breast cancer
Presenter: Sanjna Rajput
Session: Poster session 12
1905P - Impact of proactive callback in patients with solid tumors receiving systemic therapy: A meta-analysis
Presenter: Jacqueline Savill
Session: Poster session 12